Masterhead

Thank you for visiting palo-alto.gate2bay.com. Fill in the form below:

Name/Corp.:

E-mail:

Subject:

Message:

Ocera to Announce Additional Encouraging Results from its Phase 2b STOP-HE Study of IV OCR-002 in Patients with Hepatic Encephalopathy

Published Monday March 13

Food and Drug Administration (FDA) for the treatment of hyperammonemia and resultant hepatic…

We are very encouraged by the additional study data indicating IV OCR-002 provided clinical benefit over placebo in other parameters as well, such as the Physician Overall Evaluation, Model for End-Stage Liver Disease scores, and in renal function as measured by the change from baseline in Blood Urea Nitrogen levels, stated Stan Bukofzer, Doctor of Medicine Chief Medical Officer of Ocera.

Initial STOP-HE results reported in Thu Jan 1 1970 included:

Additional results to be presented today include:

Article length: About 840 words.
Read more at Drugs

google-468x60a

Share This Post

DeliciousDiggGoogleStumbleuponRedditTechnoratiYahooBloggerMyspaceRSS

selfad-writeart-b